BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2010

Mar 16, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2010-03-15

Reporting Person: HOROVITZ ZOLA P (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-03-15	Common Stock	M	10000	$2.60	Acquired	13000	Direct
2010-03-15	Common Stock	S	10000	$7.215	Disposed	3000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-03-15	Stock Option (Right to Buy)	$2.60	M	10000	Disposed	2013-05-14	Common Stock (10000)	Direct

Footnotes

F1: Transacted under a 10b5-1 plan that was adopted on 11/24/2009.

F2: The price in column 4 is a weighted average price. The prices actually ranged from $7.11 to $7.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.